FindTrial
Sign In

Treatment of warts (viral infection)

Open labelled prospective study of intralesional tuberculin PPD for treatment of warts.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/009077
Enrollment
50
Registered
2017-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- MULTIPLE, RECURRENT AND RECALCITRANT WARTS

Interventions

Control Intervention1: TUBERCULIN PPD 5TU: 0.1ml of tuberculin PPD injected into single wart every 2 wks for 5 sessions

Sponsors

PRAGATHIS
Lead Sponsor
DR SHRUTAKIRTHI D SHENOI
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing Tuberculin PPD for recurrent, reacalcitrant warts, Multiple ( >3) and extensive warts

Exclusion criteria

Exclusion criteria: 1) Patients not willing to give consent 2) Pregnant and lactating women 3) Hypersensitivity or allergy to tuberculin

Design outcomes

Primary

MeasureTime frame
To record the improvement with intralesional tuberculin PPD in treatment of multiple, recurrent and recalcitrant wartsTimepoint: OUTCOME ASSESSED AT THE END OF 5 SESSIONS (3 MONTHS)—

Secondary

MeasureTime frame
To record the improvement with intralesional tuberculin PPD in treatment of multiple, recurrent and recalcitrant wartsTimepoint: outcome is assessed at every interval i.e 2 wks—

Countries

India

Contacts

Public ContactPRAGATHI S

KASTURBA MEDICAL COLLEGE

pragsankineni@gmail.com9908630783

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026